

**27-28 June 2026**

Al Ain Rotana Hotel, Al Ain, UAE.

## CONFERENCE PROGRAM

**DAY 1**



**27 June 2026 (Saturday)**



**08:30 - 6:00**

08:30 - 08:40  
Welcome and Orientation  
Best of ASCO 2026  
**Conference Chair: Dr. Khalid Balaraj (Tawam, Al Ain)**

### SESSION 1: EARLY BREAST CANCER, SURGERY & PREVENTION (8:40 - 10:40)

Moderators: Dr. Mouza Al Ameri (Tawam, Al Ain) | Dr. Abdul Rahman Sumaida (Tawam, Al Ain)  
Dr. Soni Soumian (Tawam, Al Ain)

08:40 - 08:50	Abstract 500: First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer. <b>Dr. Batool Mamdouh Aboud (Saudi German Hospital, Ajman)</b>
08:50 - 09:00	Abstract LBA503: Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial. <b>Dr. Bassel Jallad (CCAD, Abu Dhabi)</b>
09:00 - 09:10	Abstract LBA506: Final analysis of neoadjuvant plus adjuvant pembrolizumab in high-risk early triple-negative breast cancer (KEYNOTE-522). <b>Dr. Aref Chehal (SSMC, Abu Dhabi)</b>
09:10 - 09:20	Abstract 501: Baseline gene expression prognostic/predictive analysis with adjuvant ribociclib plus NSAI in early breast cancer (NATALEE). <b>Dr. Fathi Azribi (American Hospital, Dubai)</b>
09:20 - 09:40	Main Lead Scientific Partner Led Sponsored Session <b>To be decided</b>
09:40 - 09:50	Abstract LBA515: Role of neoadjuvant versus adjuvant chemotherapy, dose density and schedule in high-risk HR-positive/HER2-negative breast cancer: ADAPT/PlanB pooled analysis. <b>Dr. Soha Mohammed Abdelbaky Talima (Affiliation TBC)</b>
09:50 - 10:00	Abstract 1021A: Analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan plus pertuzumab (DESTINY-Breast09). <b>Dr. Husam Marashi (Tawam, Al Ain)</b>
10:00 - 10:10	Abstract 10515: Low-dose tamoxifen for pre-cancer and early disease: A pooled analysis by menopausal status. <b>Dr. Avanthi Peddireddygar (NMC Royal DIP, Dubai)</b>
10:10 - 10:20	I-SPY2.2: Neoadjuvant rilvegostomig plus trastuzumab deruxtecan in high-risk HR-positive/HER2-negative disease. <b>Dr. Maroun El Khoury (American Hospital, Dubai)</b>
10:20 - 10:40	Main Lead Scientific Partner Led Sponsored Session <b>To be decided</b>

\*Subject to changes

10:40 - 11:00

**Coffee Break / Networking****SESSION 2: METASTATIC BREAST CANCER (11:00 - 12:30)**Moderators: Dr. Emad Dawoud (Tawam, Al Ain) | Dr. Sundus Yahya (Tawam, Al Ain) | Dr. Dina Hamza (Dubai Hospital, Dubai)  
Dr. Nouri Bennini (Tawam, Al Ain)

11:00 - 11:10	Abstract 1005: Efficacy and safety of tucatinib versus placebo combined with trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer by stratified subgroups (HER2CLIMB-05). <b>Dr. Dorai Ramanathan (Al Zahra Hospital, Dubai)</b>
11:10 - 11:20	Abstract LBA1006: Giredestrant plus palbociclib versus letrozole plus palbociclib as first-line therapy in ER-positive/HER2-negative locally advanced or metastatic breast cancer: persevERA BC. <b>Dr. Saeed Rafii (Mediclinic City Hospital, Dubai)</b>
11:20 - 11:30	Abstract LBA1007: First-line camizestrant for emergent ESR1 mutations in advanced breast cancer: Final PFS2 from SERENA-6. <b>Dr. Dina Hamza (Dubai Hospital, Dubai)</b>
11:30 - 11:50	Main Lead Scientific Partner Led Sponsored Session <b>To be decided</b>
11:50 - 12:00	Abstract LBA1000: ASCENT-04: Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in previously untreated PD-L1-positive metastatic triple-negative breast cancer. <b>Dr. Aladdin Marraoui (GICC, Abu Dhabi)</b>
12:00 - 12:10	Abstract 1014: Biomarker subgroup efficacy analysis of sacituzumab govitecan versus chemotherapy in first-line TNBC, ASCENT-03. <b>Dr. Sundus Yahya (Tawam, Al Ain)</b>
12:10 - 12:30	Main Lead Scientific Partner Led Sponsored Session <b>To be decided</b>

12:30 - 02:00

**Lunch Break / Networking****SESSION 3: GASTROINTESTINAL ONCOLOGY (02:00- 03:30)**

Moderators: Dr. Aswatha Ramesh (Tawam, Al Ain)

02:00 - 02:10	Abstract 102: Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study. <b>Dr. Dhanaraju Muniswamy (NMC Al Nahda/DIP, Dubai)</b>
02:10 - 02:20	Abstract LBA3503: BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). <b>Dr. Syed Monawer Karim (King's Cancer Care Centre, Dubai)</b>
02:20 - 02:30	Abstract LBA3517: AZUR-1: A phase II study of neoadjuvant dostarlimab monotherapy in patients with dMMR/MSI-H locally advanced rectal cancer. <b>Dr. Sonia Otsmane (Burjeel Medical City, Abu Dhabi)</b>
02:30 - 02:50	Platinum Scientific Partner Led Sponsored Session <b>To be decided</b>
02:50 - 03:00	Abstract LBA4000: Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants... <b>Dr. Abdul Rahman El Kinge (NMC Royal, Sharjah)</b>
03:00 - 03:10	Abstract LBA5: Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs. chemotherapy in previously treated patients with metastatic pancreatic adenocarcinoma (mPDAC): Primary analysis from the phase 3 RASolute 302 study. <b>Dr. Cherian Thampy (NMC, Abu Dhabi)</b>
03:10 - 03:30	Platinum Scientific Partner Led Sponsored Session <b>To be decided</b>

\*Subject to changes

03:30 - 03:50

**Coffee Break / Networking****SESSION 4: GU, PROSTATE & GYNECOLOGIC ONCOLOGY (03:50 - 06:00)**Moderators: Dr. Nouri Bennini (Tawam, Al Ain) | Dr. Aftab Ahmad Bhatti (Tawam/SMTC, Al Ain)  
Dr. Khalifa Alkaabi (Tawam, Al Ain)

03:50 - 04:00	Abstract LBA1: Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs. placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced... <b>Dr. Farooq Latif (Dubai Health, Dubai)</b>
04:00 - 04:10	Abstract 5001: Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ). <b>Dr. Sundus Yahya (Tawam, Al Ain)</b>
04:10 - 04:20	Abstract 5005: Cognitive effects of darolutamide vs. enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology. <b>Dr. Faraz A. Khan (American Hospital Dubai, Dubai)</b>
04:20 - 04:30	Abstract 108: An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304). <b>Dr. Deborah Mukherji (CMC Hospital, Dubai)</b>
04:30 - 04:40	Abstract 4504: Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer. <b>Dr. Aisha Alsalamy (SSMC, Abu Dhabi)</b>
04:40 - 05:00	Gold Scientific Partner Led Sponsored Session <b>To be decided</b>
05:00 - 05:10	Abstract 4507: Enfortumab vedotin plus pembrolizumab (EV+P) vs. chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). <b>Dr. Reham Omar (NMC Royal, Sharjah)</b>
05:10 - 05:20	Abstract 5505: CHRONO: A randomized phase II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer. <b>Dr. Muhammad Nasim (Tawam, Al Ain)</b>
05:20 - 05:30	Abstract 5506: A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FR $\alpha$ )-high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34). <b>Dr. Hassan Jaafar (Burjeel Cancer Institute, Abu Dhabi)</b>
05:30 - 05:40	Abstract 5517: Effects of short-term fasting compared to free diet in ovarian cancer patients: Results from a two-arm pilot randomized trial. <b>Ms. Ruqaya Suhail Juma Marzouq Alshamsi (Tawam Hospital, Al Ain)</b>
05:40 - 06:00	Gold Scientific Partner Led Sponsored Session <b>To be decided</b>

06:00

**End of Day 1 – Main Program**

\*Subject to changes

**27-28 June 2026**

Al Ain Rotana Hotel, Al Ain, UAE.

## CONFERENCE PROGRAM

**DAY 2**



**28 June 2026 (Sunday)**



**09:00 - 5:30**

### SESSION 5: LUNG CANCER PRACTICE-CHANGING UPDATES (09:00 - 11:50)

Moderators: Dr. Emad Dawoud (Tawam, Al Ain) | Dr. Mariam Almarashda (Tawam/STMC, Al Ain)  
Dr. Omran El Koha (Tawam, Al Ain)

09:00 - 09:30	Scientific Partner Led Sponsored Session <b>To be decided</b>
09:30 - 09:40	Abstract LBA3: Event-Free Survival with Adjuvant Selpercatinib in Stage IB-III A RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial. <b>Dr. Syed Tirmazy (Dubai Hospital, Dubai)</b>
09:40 - 09:50	Abstract 8000: Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST). <b>Dr. Almurtadha Mula (SSMC, Abu Dhabi)</b>
09:50 - 10:20	Eli Lilly Scientific Partner Led Sponsored Session <b>To be decided</b>
10:20 - 10:30	Abstract LBA4: Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial. <b>Dr. Hassan Shahryar (SSMC, Abu Dhabi)</b>
10:30 - 10:50	<b>Coffee Break / Networking</b>
10:50 - 11:10	Main Lead Scientific Partner Led Sponsored Session <b>To be decided</b>
11:10 - 11:20	Abstract LBA8500: Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of WU-KONG28. <b>Dr. Mudhasir Ahmad (Lifecare Musaffah, Abu Dhabi)</b>
11:20 - 11:30	Abstract 8506: Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC. <b>Dr. Diaeddine Trad (Tawam, Al Ain)</b>
11:30 - 11:50	J&J Scientific Partner Led Sponsored Session <b>To be decided</b>

\*Subject to changes

## SESSION 6: QUALITY, CARE DELIVERY & SUPPORTIVE CARE (11:50 - 12:30)

Moderators: Dr. Khalid Balaraj (Tawam, Al Ain) | Dr. Maroun El Khoury (American Hospital, Dubai)

11:50 - 12:00	Abstract 11000: The association of GLP-1 receptor agonist use with survival and immune-related adverse events in patients receiving immune checkpoint inhibitors: A multi-institutional real-world analysis. <b>Dr. Najeeb Behzad Mohammed (Zulekha Hospital, Sharjah)</b>
12:00 - 12:10	Abstract 11005: Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors. <b>Dr. Yaara Alkanash (Affiliation TBC)</b>
12:10 - 12:20	Abstract 1508: Essential but unaffordable: Real-world costs of WHO essential cancer medicines in a low-income setting. <b>Dr. Dana (Affiliation TBC)</b>
12:20 - 12:30	Session discussion and audience Q&A <b>To be decided</b>

### 12:30 - 02:00 Lunch Break / Networking

## SESSION 6: HEMATOLOGIC MALIGNANCIES, MELANOMA & IMMUNOTHERAPY

(02:00 - 03:40)

Moderators: Dr. Arif Alam (Tawam Hospital, Al Ain) | Dr. Salman Ahmed; Dr. Soni Soumian (Tawam, Al Ain)

02:00 - 02:10	Abstract LBA6500: Selinexor plus ruxolitinib in JAK inhibitor-naive myelofibrosis: Phase 3 SENTRY trial <b>Dr. Dalia Elshorbagy (SSMC, Abu Dhabi)</b>
02:10 - 02:20	Abstract LBA7000: frontMIND: Phase 3 study of tafasitamab plus lenalidomide and R-CHOP for patients with newly diagnosed diffuse large B-cell lymphoma. <b>Dr. Hani Yousif Osman (Tawam Hospital, Al Ain)</b>
02:20 - 02:30	Abstract 7008: Mediterranean CD19 genetic variations and potential influence on CAR T-cell therapy efficacy: Implications for population-tailored immunotherapy. <b>To be decided</b>
02:30 - 02:40	Abstract LBA7506: Mezigdomide, carfilzomib, and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma: SUCCESSOR-2. <b>Dr. Tala Achkar (Emirates Specialty Hospital, Dubai)</b>
02:40 - 03:00	Platinum Scientific Partner Led Sponsored Session <b>To be decided</b>
03:00 - 03:10	Abstract 7507: MajesTEC-9: Teclistamab monotherapy vs investigator's choice in relapsed/refractory multiple myeloma. <b>Dr. Amar Lal</b>
03:10 - 03:20	Abstract LBA9503: Darovasertib plus crizotinib versus investigator's choice as first-line treatment in HLA-A2-negative metastatic uveal melanoma: OptimUM-02. <b>Dr. Roshan Koshy Jacob (NMC Royal, Sharjah)</b>
03:20 - 03:30	Abstract LBA9505: Updated outcomes from STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, ECOG-ACRIN EA6174. <b>Dr. Mawada Hussein (Burjeel Medical City, Abu Dhabi)</b>
03:30 - 03:40	Abstract 9518: 3-year landmark overall survival analysis of RP1 plus nivolumab in anti-PD-1-failed melanoma from IGNUYE. <b>Dr. Rajitha Lokadasan (NMC Specialty, Abu Dhabi)</b>

### 03:40 - 04:00 Coffee Break / Networking

\*Subject to changes

## SESSION 8: SARCOMA, CNS & PRECISION THERAPEUTICS (04:00 - 05:20)

Moderators: Dr. Omran El Koha (Tawam, Al Ain) | Dr. Salman Ahmed | Dr. Mahdi Al-Taher

04:00 - 04:10	Abstract LBA2: SARC041: Abemaciclib versus placebo in advanced dedifferentiated liposarcoma. <b>Dr. Nouri Bennini (Tawam, Al Ain)</b>
04:10 - 04:20	Abstract 11500: PEAK study of bezuclastinib plus sunitinib vs sunitinib in advanced GIST. <b>Dr. Bharadwaj Ponnada (Zulekha, Dubai)</b>
04:20 - 04:40	Platinum Scientific Partner Led Sponsored Session <b>To be decided</b>
04:40 - 04:50	Abstract LBA2000: Post-operative stereotactic radiation versus cesium-131 tile-based radiation after resection for newly diagnosed brain metastases. <b>Dr. Nadeem Pervez (Radiation Oncology, UAE)</b>
04:50 - 05:00	Abstract 2502: DART: Dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers. <b>Dr. Moustafa Emad Al Daly (IMH Dubai)</b>
05:00 - 05:00	Gold Scientific Partner Led Sponsored Session <b>To be decided</b>
05:20 - 05:30	Best of ASCO 2026 closing summary <b>Conference Chair: Dr. Khalid Balaraj (Tawam, Al Ain)</b>

05:30

**End of Conference**

*\*Subject to changes*